Insights
Search Results
Newsletters
6.03.26
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
6.03.26
Wilson Sonsini Advises Isomorphic Labs on $2.1 Billion Series B Investment Round
On May 12, 2026, Isomorphic Labs, an AI-first drug design and development company, announced it has raised $2.1 billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base. Wilson Sonsini Goodrich & Rosati advised Isomorphic Labs on the transaction.
Client Highlights
6.02.26
Firm Advises Noctrix on Acquisition by Resmed
On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
5.13.26
Wilson Sonsini Advises Whitehawk Therapeutics on $87.5 Million PIPE Financing
On May 13, 2026, Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate cancer treatments, announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $87.5 million, before deducting placement agent fees and other private placement expenses. The PIPE financing includes participation from existing investors including Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1 Capital Management, Acuta Capital Partners, StemPoint Capital LP, Invus, as well as members of the company’s executive team. Wilson Sonsini Goodrich & Rosati advised Whitehawk on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Represents Investors in Windward Bio’s $165 Million Crossover Financing
On May 4, 2026, Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. Wilson Sonsini Goodrich & Rosati represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in the transaction.
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Client Highlights
4.20.26
Wilson Sonsini Advises Novo Holdings on Route 92 Medical’s $50 Million Growth Financing
On April 7, 2026, Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, announced a $50 million growth financing led by Novo Holdings. New investor Sectoral Asset Management and existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group joined in the financing round. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.
Client Highlights
4.17.26
Firm Advises Neurona Therapeutics on Acquisition by UCB
On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.
Client Highlights
4.16.26
Wilson Sonsini Advises Terremoto on IP Matters Related to $108 Million Series C
On April 15, 2026, Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, announced the closing of a $108 million Series C financing round. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, and participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. Wilson Sonsini Goodrich & Rosati advised Terremoto on IP matters related to the transaction.
Client Highlights
4.13.26
Wilson Sonsini Advises Ultralight on $9.3 Million Seed Funding
On April 13, 2026, Ultralight, the AI-native operating system for modern medicine, announced that it has raised $9.3 million in seed funding. The round was led by The General Partnership, with participation from Wisdom Ventures, Anthemis Group, Emerson Collective, GSBackers, and various angel investors. Wilson Sonsini Goodrich & Rosati advised Ultralight on the transaction.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Ultralight’s platform automates busywork, surfaces deep clinical insights, and frees clinicians to practice high-touch medicine. Designed for clinicians who lead functional, integrative, or longevity practices, Ultralight unifies electronic health records, practice management, and patient engagement in one vertical SaaS stack, with powerful AI natively built in.
The Wilson Sonsini team that advised Ultralight on the financing includes Lang Liu and Oliver Zhou.
For more information, please see Ultralight CEO Sunita Mohanty’s LinkedIn post and this Axios article.
Podcasts
4.09.26
NextGen VC Podcast – From Scalpel to Term Sheet: Rich Gaster of venBio
In the latest episode of the NextGen VC Podcast, Rich Gaster, M.D., Ph.D., managing partner at venBio, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to discuss what it takes to go from performing reconstructive plastic surgeries at Harvard to becoming a managing partner at one of biotech’s most focused venture firms. He traces a career path that runs through Stanford M.D.-Ph.D. training, two grad school start-ups, the company-building engine at Third Rock Ventures, and the founding team of Pliant Therapeutics before landing at venBio, where he helped engineer three back-to-back acquisitions in a single quarter.